- Title
- RINATABART SESUTECAN MONOTHERAPY IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: PART F OF THE PHASE 1/2 RAINFOL™-01 STUDY
- Creators
- Debra Richardson - University of OklahomaGottfried Konecny - UCLA HealthElizabeth Lee - Dana-Farber Cancer InstituteIra Weiner - Karmanos Cancer Institute, Detroit, United States of AmericaLyndsay J. Willmott - PhoenixJustin Call - StartJessica Thomes Pepin - Minnesota OncologyAndrea Jewell - University of Kansas Medical CenterCara Mathews - Brown UniversityLeigh Seamon - StartJoseph Buscema - Arizona OncologyBradley Monk - Florida Cancer Specialists and Research Institute, West Palm Beach, United States of AmericaElizabeth Guancial - Florida Cancer Specialists and Research Institute, Internal Medicine, Medical Oncology/hematology, Sarasota, United States of AmericaDouglas Orr - Mary Crowley Cancer Research, Dallas, United States of AmericaAnton Melnyk - Texas Oncology-Abilene, Abilene, United States of AmericaMichael Gillespie - GenmabNurgul Kilavuz - GenmabTeng Jin Ong - Genmab AS, Princeton, United States of AmericaEdward Kavalerchik - Genmab AS, Princeton, United States of AmericaNoelle Cloven - Fondazione Ricerca Traslazionale
- Publication Details
- International journal of gynecological cancer, Vol.35(11), p.102612
- Publisher
- Elsevier Inc
- Identifiers
- 991006235738302656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
RINATABART SESUTECAN MONOTHERAPY IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: PART F OF THE PHASE 1/2 RAINFOL™-01 STUDY
International journal of gynecological cancer, Vol.35(11), p.102612
11/2025
Metrics
5 Record Views